Biocon’s skin drug sales surge despite limited Covid-19 study

Firm hopes the sales of itolizumab will pick up as it enters Ph-4 trials

Biocon’s repurposed psoriasis drug itolizumab has seen sevenfold jump in sales after it got an emergency use authorisation for Covid-19 treatment. The drug, however, is yet to be a part of the clinical management protocol of the health ministry for treatment of Covid-19, which implies that the government has not yet recommended it as an effective treatment.

With Phase-4 clinical trials on, sales may see a further uptick if the data supports it helps Covid-19 patients, said experts. The data from market research firm AIOCD AWACS showed that volumes shot up seven times in August (350 units) from just 50 units in July when it received the approval. In June, the drug did not show sales.

In India, itolizumab, known by the brand name Alzumab, has been priced at ~8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to ~32,000. In a few cases, a patient might need two more vials.

To repurpose the drug for Covid19, the previous trial was done on a cohort of 30 patients suffering from moderate to severe acute respiratory disorder syndrome due to Covid-19. Of them, 20 received itolizumab and 10 received standard care. The 20 who were administered itolizumab recovered fully, the firm said. Three of the 10 patients under standard care died.

After many experts pointed out that the study was conducted on limited number of patients, Biocon has started a Phase-4 post marketing surveillance of the drug on a pool of 300 patients that will take a couple of months to complete.

A Phase-4 study is a follow-up on real world evidence on the efficacy and safety of a drug.

“When we did a proof of concept study, we got the emergency use authorisation because it is already an approved drug and has a lot of safety data,” said Kiran Mazumdar-shaw, executive chairperson, Biocon.

Satyanarayana Mysore, head of department of interventional pulmonology, Manipal Hospitals, who used the drug on Covid-19 patients said the use of the drug would rise if more supporting data emerges. Mysore used the drug on two patients when Roche’s tocilizumab was not available. “Both responded well. But two is a small number,” Mysore said.

Shaw had earlier said Biocon sees itolizumab as a blockbuster opportunity for the firm and has been working towards ramping up its capacity.